Go to main content

With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan. AOP Orphan is an Austrian pharmaceutical company and a European pioneer in Rare Diseases.

Dr. Christoph Klade has over 15 years of professional experience—ranging from basic research to product development. After he finished his degree in Biochemistry, Microbiology and Immunology, Dr. Christoph Klade began his career at Boehringer Ingelheimer where he focused on cancer vaccines, tumor immunology, tumor contingents and interferon.  Later Dr. Klade switched to Intercel. While there, he spent 12 years in various leadership positions and guided over 20 clinical studies (from phase 1 to 4) in different indications. In addition, he developed vaccines and was responsible for the worldwide registration of the Japanese encephalitis tropical disease vaccine. At AOP Orphan, Dr. Christoph Klade will also be responsible for Research and Development. There he will further strengthen AOP Orphan’s recognized competence in the specialized sector of Rare Diseases.


AOP Orphan Pharmaceuticals AG
Mag. Daniela Gruber
Wilhelminenstraße 91/IIf
1160 Wien
T +43 1 503 72 44-42
F +43 1 503 72 44-61